首页> 外文期刊>CNS oncology. >Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience
【24h】

Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience

机译:3D-CRT可以达到所需的剂量分布到胶质母细胞瘤中的靶向和桨状吗?高等教育中心经验

获取原文
       

摘要

Aim: The purpose of the study is to perform a dosimetric analysis of the doses received by planning target volume and organ at risks in the postoperative glioblastoma by using 3D-conformal radiotherapy to a total dose of 60?Gy in 30 fractions. Materials &?Methods: All patients received concurrent temozolomide every day, and this was followed by adjuvant temozolomide of 5 days of treatment per month. Results: More than 98% of patients were treated with a dose of 60?Gy. Doses were analyzed for the normal whole brain, tumor volume, as well as all the organs at risk. Conclusion: Given the grave prognosis and the limited survival of glioblastoma despite the best treatment available, makes 3D-conformal radiotherapy an equally acceptable treatment option.
机译:目的:该研究的目的是通过在术后胶质母细胞瘤的风险下使用3D-Conformal放射治疗在30级分数中的总剂量为60μm,对术后胶质母细胞瘤的风险进行剂量分析。材料&?方法:所有患者每天接受并发替莫唑胺,其次是每月5天治疗的佐剂替斯替替莫唑胺。结果:98%以上的患者用60℃的剂量治疗。对正常全脑,肿瘤的体积以及风险的所有器官进行分析剂量。结论:鉴于可用治疗最佳的治疗,鉴于坟墓预后和胶质母细胞瘤的有限存活,使3D-全成形放疗同样可接受的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号